It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The ability of bacterial pathogens to establish recurrent and persistent infections is frequently associated with their ability to form biofilms. Clostridioides difficile infections have a high rate of recurrence and relapses and it is hypothesized that biofilms are involved in its pathogenicity and persistence. Biofilm formation by C. difficile is still poorly understood. It has been shown that specific molecules such as deoxycholate (DCA) or metronidazole induce biofilm formation, but the mechanisms involved remain elusive. In this study, we describe the role of the C. difficile lipoprotein CD1687 during DCA-induced biofilm formation. We showed that the expression of CD1687, which is part of an operon within the CD1685-CD1689 gene cluster, is controlled by multiple transcription starting sites and some are induced in response to DCA. Only CD1687 is required for biofilm formation and the overexpression of CD1687 is sufficient to induce biofilm formation. Using RNAseq analysis, we showed that CD1687 affects the expression of transporters and metabolic pathways and we identified several potential binding partners by pull-down assay, including transport-associated extracellular proteins. We then demonstrated that CD1687 is surface exposed in C. difficile, and that this localization is required for DCA-induced biofilm formation. Given this localization and the fact that C. difficile forms eDNA-rich biofilms, we confirmed that CD1687 binds DNA in a non-specific manner. We thus hypothesize that CD1687 is a component of the downstream response to DCA leading to biofilm formation by promoting interaction between the cells and the biofilm matrix by binding eDNA.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Hunault, Lise 2 ; England, Patrick 3 ; Monot, Marc 4
; Pipoli Da Fonseca, Juliana 4 ; Matondo, Mariette 5
; Duchateau, Magalie 5 ; Tremblay, Yannick D. N. 6 ; Dupuy, Bruno 7 1 Laboratoire Pathogenèse des Bactéries Anaérobies, Institut Pasteur, Université Paris-Cité, UMR-CNRS 6047, Paris, France
2 INSERM UMR1222, Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université Paris-Cité, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389); Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, INSERM, CNRS, Paris, France (GRID:grid.463810.8)
3 Institut Pasteur, CNRS UMR3528, Plateforme de Biophysique Moléculaire, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535)
4 Institut Pasteur, Plateforme Technologique Biomics, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535)
5 Institut Pasteur, Plateforme Proteomic, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535)
6 University of Saskatchewan, Department of Biochemistry, Microbiology and Immunology, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
7 Laboratoire Pathogenèse des Bactéries Anaérobies, Institut Pasteur, Université Paris-Cité, UMR-CNRS 6047, Paris, France (GRID:grid.25152.31)




